Andere talen Kiora Pharmaceuticals, Inc.

Aandelen

KPRX

US49721T3095

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 13-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,5097 ^USD	+4,83%		-2,17%	-2,43%

25/03	Kiora Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
09/02	KIORA PHARMACEUTICALS, INC. : HC Wainwright geeft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	13/05
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	10/05
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	10/05
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	08/05
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	06/05
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12/04
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11/04
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05/04
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28/03
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25/03
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08/03
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	01/02
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01/02
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01/02
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	31/01
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	31/01
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	17/11
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	09/11
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kiora Pharmaceuticals, Inc.

Aandelen

KPRX

US49721T3095

Andere talen

Filters